OpEx and Profitability
Q: What are your expectations for R&D and SG&A expenses?
A: We plan to keep R&D spending low this year, modeling it at roughly $2.5 million, less than half of last year [1]. G&A expenses are expected to be somewhat down from last year, as we're continuing to look for opportunities to reduce expenses [1]. Marketing spend will scale with our business, with variable sales and marketing expense at about 30% on a blended basis [1]. G&A was seasonally high in Q1 due to audit-related costs but should be down in the remaining quarters [1].

VA Channel Growth
Q: How sustainable is your growth in the VA channel?
A: We believe growth is sustainable by going deeper into existing facilities [6]. It's more efficient to expand within facilities where we're already known, allowing our sales team to engage with more prescribers across departments [6]. We're also scaling our business using independent agents who are incentivized to sell our products alongside others [6].

DoD and TAC-STIM Business
Q: What is the outlook for TAC-STIM sales to the DoD?
A: We're receiving contingent purchase orders, pending the DoD budget process [8]. While we have a funnel of orders, we lack visibility on timing due to past delays from continuing resolutions in Congress [8]. We're not providing revenue guidance until we know delivery and revenue recognition dates [8].

Truvaga Plus Expansion
Q: Are there plans to market Truvaga Plus through other channels?
A: Yes, we consider expanding into additional distribution channels a key initiative for 2025 [11]. After ensuring the product launch proceeds smoothly over the next 30-60 days, we'll look to aggressively expand into both brick-and-mortar and online direct-to-consumer channels [11].

New Indications
Q: When can we expect approval for PTSD indication?
A: While we're aware of off-label use for PTSD in VA hospitals and cash pay businesses, we won't speculate on FDA timing for label extension [7]. We don't track diagnoses in VA prescriptions, so we can't quantify current use for PTSD or Parkinson's [7].

Inventory Management
Q: How do you expect inventories to play out this year?
A: We're still running heavy on inventory relative to daily sales due to uncertainty in product mix [2]. As we better understand sales between products like the Truvaga 350 and Plus, we aim to steadily reduce inventory levels and generate cash from it [2].

Newcastle Study Update
Q: Is there an update on the Newcastle Parkinson's study?
A: The study is investigator-initiated and out of our control [5]. Last patient visit was in late December 2023, and we're waiting for the investigators to share the data when they're ready [5].

[Indiscernible] Healthcare Agreement
Q: Do you have an update on your agreement with [Indiscernible] Healthcare?
A: The back office is fully set up, and prescriptions can be accepted and adjudicated [12]. Our field sales team is now focused on generating demand by developing prescriber champions, and we're receiving excellent reception [12]. We expect to see revenue impact before the end of the year [12].

Recurring Revenue from Truvaga Plus
Q: Will there be recurring revenue from Truvaga Plus apps?
A: Yes, that's part of our product development pipeline for 2025 and 2026 [13]. We plan to leverage mobile app connectivity, integrating with health apps like Apple Health, which could create new value propositions [13].

Interest from Sports Leagues
Q: Any further interest from the NFL or other sports leagues?
A: There's a lot of interest, but nothing we can publicly discuss [14]. The NFL research program won't disclose which teams are using our products, which is frustrating as a football fan [14].